Association of baloxavir marboxil prescription with subsequent medical resource utilization among school‐aged children with influenza
- 20 February 2021
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 30 (6), 779-786
- https://doi.org/10.1002/pds.5207
Abstract
Purpose Baloxavir marboxil is a novel antiviral agent for influenza, introduced into clinical practice in 2018. A concern remains about the variant virus with reduced susceptibility after baloxavir exposure and its clinical consequences such as healthcare‐seeking behavior. Methods Using a healthcare database in Japan, we compared the medical resource use following baloxavir and neuraminidase inhibitors (NAIs) treatment among children aged 7–15 years. The study period was from December 2018 to March 2019. The primary endpoint was the composite of hospitalization, laboratory and radiological tests, and antibiotic use over 1–9 days of antiviral treatment. As exploratory analyses, secondary outcomes being each single component of the primary composite were assessed and subgroup analyses comparing baloxavir with each NAI were done. Results Data from 115 867 prescriptions in 115 238 children were analyzed (median age: 10 years; severe influenza risk in 26%; baloxavir accounting for 43%). Overall, baloxavir use did not increase subsequent medical resource utilization in the composite endpoint (adjusted odds ratio [aOR]: 1.04; 95% confidence interval [CI]: 0.99–1.09; P = 0.14), as were likelihoods of other secondary outcomes. In the subgroup analysis, baloxavir use was associated with higher medical resource use than oseltamivir (aOR: 1.21; 95% CI: 1.13–1.31; P < 0.001) and lower resource use than zanamivir (aOR: 0.93; 95% CI 0.86–1.00; P = 0.040). Conclusions Based on a single‐year experience in Japan, prescribing baloxavir rather than NAIs did not increase medical resource utilization within 9 days of treatment, except in one exploratory comparison with oseltamivir.Keywords
Funding Information
- Japan Agency for Medical Research and Development (19lk0201061h0004)
- Japan Society for the Promotion of Science (18K14950, 20H03941)
This publication has 31 references indexed in Scilit:
- Validity of diagnoses, procedures, and laboratory data in Japanese administrative dataJournal of Epidemiology, 2017
- Japanese Surveillance Systems and Treatment for InfluenzaCurrent Treatment Options in Infectious Diseases, 2016
- Adjust for Multiple Comparisons? It’s Not That SimpleThe Annals of Thoracic Surgery, 2016
- Promise and Limitations of Big Data Research in Plastic SurgeryAnnals of Plastic Surgery, 2016
- Oseltamivir for influenza infection in children: risks and benefitsExpert Review of Respiratory Medicine, 2015
- The rise of big clinical databasesBritish Journal of Surgery, 2015
- The burden of influenza in England by age and clinical risk group: A statistical analysis to inform vaccine policyJournal of Infection, 2014
- Six Persistent Research MisconceptionsJournal of General Internal Medicine, 2014
- How to Use a Subgroup AnalysisJAMA, 2014
- Oseltamivir Prescription and Regulatory Actions Vis-à-Vis Abnormal Behavior Risk in Japan: Drug Utilization Study Using a Nationwide Pharmacy DatabasePLOS ONE, 2011